Tango Therapeutics, Inc.

Tango Therapeutics, Inc. came to market through BCTG Acquisition Corp. (Nasdaq: BCTG), a blank check company that completed its initial public offering in October 2020 and was sponsored by BCTG Sponsor LLC, an affiliate of Boxer Capital, a healthcare-focused investment firm. The SPAC completed its business combination with Tango Therapeutics in August 2021, taking the oncology-focused biopharmaceutical company public on Nasdaq. Tango Therapeutics is engaged in the discovery and development of precision cancer medicines using a synthetic lethality approach. The company filed the referenced 8-K with the SEC on May 13, 2026. Visit SpacDesk and sign up for full access to filings, deal timelines, and sponsor analytics for BCTG and hundreds of other SPAC transactions.